- All
- 2026-06-11 [Thursday]
- 2026-06-12 [Friday]
- 2026-06-13 [Saturday]
- 2026-06-14 [Sunday]
- All
- A1-A (102-107)
- A1-A101
- A1-A102
- A1-A103
- A1-A104
- A1-A (105-107)
- A1-A108
- A1-A109
- A1-A110
- A2-A206
- A2-A207
- A2-A208
- A2-A213
- A2-A214
- A2-A215
- B1 Hall (Poster Area)
- B1 Hall (Exhibition Area)
2026-06-11 (Thursday)
A1-A108
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 16:13-16:21 |
Efficacy of QL1706 Combined with Intra-Arterial Intervention and Bevacizumab in Refractory Hepatocellular Carcinoma After Targeted and Immunotherapy |
Tian-Qi Zhang | Sun Yat-sen University Cancer Center, China |
| 2 | 16:21-16:29 |
TACE Combined with HAIC, TKIs, and ICIs vs TKIs plus ICIs for Unresectable BCLC Stage C Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study |
Li-Nan Yin | Harbin Medical University Cancer Hospital, China |
| 3 | 16:29-16:37 |
Safety of percutaneous transpulmonary microwave ablation for liver tumors under mechanical ventilation: a single-center retrospective study |
Yonghui Xia | |
| 4 | 16:37-16:45 |
Needle angle display-assisted CT-guided trans-thoracic radiofrequency ablation for hepatic dome tumors |
Cheng-Shi Chen | Department of interventional radiology, the affiliated cancer hospital of Zhengzhou University&Henan Cancer Hospital, Zhengzhou University, China |
| 5 | 16:45-16:53 |
A Single-Center, Prospective, Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Infusion Chemotherapy (HAIC), TKI and immunotherapy as First-Line Therapy in Patients With Unresectable Hepatocellular Carcinoma |
Tao Han | The First Affiliated Hospital of China Medical University , China |
| 6 | 16:53-17:05 |
Efficacy and Safety of HAIC Combined with Donafenib and Sintilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Prospective Phase II Study (The DoHAICs Study) |
Wei Gao | Tianjin Medical University Cancer Institute & Hospital, China |
| 7 | 17:05-17:17 |
Panel Discussion |
A LL |
